The firms will conduct PacBio whole-genome sequencing on epilepsy patients to generate variant profiles that can help the development of diagnostic assays.
The investment bank also raised its price target for the company to $15, based on PacBio's strategic plan to commercialize its long-read Sequel II system.
The sequencing firm is offering 19.4 million shares of common stock at $4.47 per share and plans to use the proceeds for product launches, among other uses.
The sequencing firm said the COVID-19 pandemic had a negative impact on revenues, which totaled $17.1 million, down from $24.6 million in the prior-year period.
In Science this week: Fiber-seq method to examine regulatory architecture, mutations in SOST associated with osteoporosis drug-linked cardiovascular events, and more.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
